News

21
mrt
2017

Walter Balestra shares his experiences on the fast-growing organization ZorgDomein Nederland

Amsterdam, 21st of March 2017 – During the third Holland Venture Growth Session, Walter Balestra (CEO of the fast-growing organization ZorgDomein Nederland) shared his experiences  on how his organization acquired a central place in the Dutch healthcare landscape. For the attendees, it was an interesting session on growth and innovation in the healthcare sector.

In 2000, ZorgDomein was cofounded by Walter Balestra out of the consulting firm Plexus. By offering a national platform which enables the connection between people who need care and people who provide care, ZorgDomein aims to organise care more efficient and more effective. In 2016 about 80% of all referrals from physicians in the Netherlands was completed via ZorgDomein. Last year the organization processed 7,4M transactions and it  had around 90 employees. Hereby taking up a central place in the Dutch healthcare landscape. With over 20 years of experience in healthcare, Walter fulfils the role of CEO of ZorgDomein Nederland since 2006. As an investor, he is also involved in several start-ups in healthcare. Walter has a background as a medical biologist specialised in brain research.

The strong growth of ZorgDomein, as well as the challenges associated with such a development, were a central topic during this Growth Session. Walter recounted vividly about the development of his company and shared his teachable moments with the attendees. The interactive character inspired the attendees, including a large number of entrepreneurs of the Holland Venture Holdings. The exchange of experience and the hands-on tips from Walter were regarded as highly valuable.



During the Holland Venture Growth Sessions we invite a successful entrepreneur to share his or her experiences in a fast-growing company with the management teams of our portfolio companies. These are interactive sessions with a focus on achieving growth by sharing experiences and tips-and-tricks in an informal setting. Around autumn, we will be organizing the fourth Holland Venture Growth Session.

14
mrt
2017

Holland Venture invests in semiconductor packaging equipment specialist Boschman Group

Amsterdam/Duiven, March 14th, 2017 – Holland Venture, a Dutch based investment firm, announced today that it completed an investment in the Boschman Group, a specialist in high-end packaging equipment for the semiconductor industry. This investment enables the Boschman Group to further commercialize their in-house developed technology and strengthen their international market position

The Boschman Group in Duiven Netherlands established in 1987 is a high-end niche player with the semiconductor packaging equipment sector. Through its subsidiaries Boschman Technology and Advanced Packaging Center they provide full solutions for the development and production of semiconductor packaging specifically in transfer-molding and silver sintering die-attach. They focus on smartcards, sensors, medical, optical and power devices. The Boschman Group has developed several unique and patented technologies that provide innovative packaging solutions for complex, advanced and demanding sensors and chips.

 ‘We see with the advance of the Internet of Things an increase of complexity in products, specifically with regard to the number of innovative sensors integrated in one device, like in smartphones for instance. Also electrical and autonomous vehicles will demand increasingly more sensors with a higher level of integration and high quality requirements as well as efficient and robust power electronics. Exactly in these type of applications the Boschman Group has a strong market position and with their patented technology they are perfectly positioned to meet the growing and ever more complex demands in these segments over the coming years. Several projects with important companies such as Semikron, Bosch, Renesas and Infineon are ongoing. A leading American manufacturer of electric vehicles (EVs) is already using Boschman Technology, which enables them to develop highly efficient power electronics in a small form factor to be used in their latest car design’, said Hubert Verbeek, Managing partner in Holland Venture

Frank Boschman, CEO of the Boschman Group, indicates that he sees Holland Venture as their ideal partner who can support them in their ambition for continuous international growth. ‘We are ready for the next step to further improve our value proposition, service and continuity. We will utilize the investment from Holland Venture additionally to strengthen our sales, invest in production capabilities and increase our innovation efforts in leading packaging technologies’.

About Holland Venture
Holland Venture has over the past 35 years invested responsibly and successfully in over 130 Dutch SMEs. With a clear strategy, they are active in the sectors Healthcare and Technology with a team that is experienced and involved in entrepreneurship. They prefer an open, sustainable and professional collaboration with each of their investments management teams in order to realize growth as a common target. Holland Venture is supported by a large network of successful entrepreneurs in these sectors.

09
mrt
2017

Holland Venture invests in Mauritsklinieken; a chain of clinics specialized in dermatological care

Amsterdam, March 9th 2017 – Together with management, Holland Venture invests in Mauritsklinieken, a chain of clinics specialized in dermatological care. As part of the transaction, shares were acquired from the founders SJMG and private equity firm Waterland. The investment enables Mauritsklinieken to further its collaboration with hospitals and general practitioners, and to expand into related specialisms.

Mauritsklinieken, founded in 2004, serves a large part of the Netherlands and provides quality care for various skin conditions. This includes both insured and uninsured care. Services include dermatology, varicose vein care, skin treatment and cosmetic care. Dermatologic care includes treatments for conditions such as treatments for eczema, psoriasis, hair loss and skin cancer. Examples of cosmetic care are eyelid and nose surgery and wrinkle treatment through fillers or botulinum toxin.

"Within the healthcare sector, we see a strong need for personal attention, innovation and knowledge sharing. This coincides with the trend that hospitals focus more on the complex care and transfer the elective care towards specialized clinics. These developments lead to better patient care which is more cost-effective. Furthermore, we see an  increased  attention by healthcare consumers for cosmetic treatments. I do see an interesting opportunity for a  quality provider like the Mauritsklinieken. Mauritsklinieken fits well within our investment focus", says Ewout Prins, managing partner Holland Venture.

Ivo Boslooper, CEO of the Mauritsklinieken, indicates that the entry of Holland Venture provides a solid foundation to take the next steps in the development of the Mauritsklinieken. The focus will be on further strengthening the cooperation with general practitioners and hospitals, and to increase care offering, both geographically and in the breadth of the offering. "A close cooperation with the  general practitioners is important for us. We put our dermatological expertise at the service of their patients. We also want to increase our cooperation with hospitals, so that they can really focus on their selected expertises. In addition to these collaborations, we want to expand the scope of our activities. This expansion may take place both organically and through acquisitions", says Ivo Boslooper.

About Holland Venture
Over the last 35 years, Holland Venture has invested responsibly and successfully in more than 130 Dutch SME’s. With a clear investment strategy, it operates in the attractive growth markets of Healthcare and Technology. Its experienced and dedicated investment team knows what entrepreneurship means. Holland Venture is committed to an open, sustainable and professional relationship with the management teams of the companies she invests in, with the common goal to achieve growth. Holland venture is supported by a broad network of successful entrepreneurs in both Healthcare and Technology.

07
mrt
2017

QSight IT strengthens position with InSpark

Inovativ and Sparked are continuing as InSpark

Amsterdam, 7 March 2017 – cloud consultancy agencies and Microsoft Gold Partners inovativ and Sparked have joined forces and are continuing as InSpark. InSpark provides a higher level of innovation to customers and enables organizations to transform in order to increase their impact and accelerate their business.

Innovate to accelerate
InSpark innovates and transforms organizations. Every aspect of a workspace and process, from management to strategy, is optimized to ensure that employees and customers get the most from technology. Demand for a full‑service digital transformation is rapidly increasing because more organizations are recognizing that real innovation accelerates the achievement of business objectives.

In the words of Laurens Frijters, Managing Director at InSpark, “that is exactly what InSpark intends to do: shape the interface between business and IT organizations so that our customers can keep pace with the market at all times and anticipate market developments.”

Full service, full force
InSpark aims to rapidly become the undisputed number one Microsoft Business and IT Partner. As InSpark Managing Partner Alex Hendrikse explained, “Sparked has implemented a tremendous number of modern workspaces, smart data solutions, and business apps. inovativ is second to none in setting up hybrid data centers and implementing mobility and security solutions. As InSpark, we are more than capable of providing full service and full force to customers.”

Unique combination

In 2014 QSight IT and inovativ started a strategic partnership aimed at bringing security to the  cloud.
 
“QSight IT and InSpark form a unique combination in the IT market, especially with their focus areas Microsoft, cloud, security and networking”, says Martijn Hakstege, CEO of QSight IT. “For a successful digital transformation, doing this transformation ‘secured’ is a necessity, explains Martijn Hakstege. “Advanced  technologies such as Big Data and Artificial Intelligence are of crucial importance to be able to keep a grip on data from information systems. The business models of QSight IT and InSpark touch and reinforce each other here .”

QSight IT senses the need from the market to be able to trust information systems in an organisation. Data are the asset of every organisation, and with an internet that is becoming increasingly unsafer, the security of data is an absolute and essential concern for every organization. With the merger between inovativ and Sparked QSight IT confirms its strategy and ambition to become the cybersecurity company for The Netherlands.

About InSpark

Stronger together
InSpark has the largest number of MVPs of all Microsoft partners in Europe. To date, its 85 consultants have brought over 500,000 users to the cloud. InSpark’s customers include SkyTeam, Hollands Kroon, Ampelmann, and Young Capital. InSpark’s board consists of Laurens Frijters, Alex Hendrikse, Dave Kiwi, and Maarten Goet. Read more at https://www.inspark.nl/.

In recent years both inovativ and Sparked earned accolades like Microsoft Gold Partner, Innovator of the Year 2016, EM+S Enterprise Elite Partner, and several FD Gazelle awards.

About QSight IT
QSight IT is a 100% Dutch IT company with an absolute focus on security, networking, cloud and risk management. QSight IT’s customer base includes organisations in the sectors of Cure & Care, Finance, Public, Manufacturing and Business Services. The company not only supplies and integrates IT technology, but also offers a wide portfolio of proactive consultancy, support and managed services.

QSight IT realises complex projects with far-sighted vision. By researching, exploring and guiding, QSight IT leads its customers into an environment in which Information Technology supports the business and security is guaranteed. QSight IT has a strategic partnership with InSpark, that combines security, networking and storage knowledge with cloud & Microsoft expertise. Read more on www.qsight.nl

13
dec
2016

Holland Venture raises 55 million for a new private equity fund

Amsterdam, 13th of December 2016 - Holland Venture has launched a new private equity fund. The capital is intended for small and medium-sized Dutch companies operating in the fields of Healthcare and Technology. The fundraising went expeditiously; the target amount of EUR 55 million was attracted within three months.

Active investment strategy
Holland Venture Entrepreneurs Fund III has a similar investment strategy as the previous funds. She invests in growing, medium-sized companies that have their headquarters in the Netherlands and are active in Healthcare and Technology. With this fund, Holland Venture facilitates management buy-outs and growth capital. Besides additional capital, Holland Venture adds value by providing knowledge, network and hands-on support. The new fund has set a target to achieve 10-12 investments in the coming years.

Experience and network in Healthcare and Technology
Since 1981, Holland Venture has built up expertise in Healthcare and Technology. Within Healthcare, she invests in medical technology, Healthcare providers and providers to Healthcare institutions. Recently, Holland Venture supported the buy-and-build strategy of dentist chain RDW and the management buyout of Humeca, a  company that develops innovative products in the field of burn surgery. In the Technology space, Holland Venture focuses on - amongst others -  software, security and big data solutions. Within the Technology space, Holland Venture focuses, amongst others, on software, security and big data solutions. As such, Holland Venture supports the buy-and-build strategy of security, networking & cloud integrator QSight IT, as well as the growth of Virtual Affairs, a company that provides digital solutions for banks and insurances.

Expeditious fundraising
Due to a positive track record, there was an extraordinary amount of interest from both existing and new investors, at home and abroad. As a result, the target amount of EUR 55 million was quickly achieved and Holland Venture could not respond to all interested limited partners. Investors in the new fund include entrepreneurs (many of which are active in Healthcare and Technology), family offices and institutional investors. With this new fund, the total assets under management exceed EUR 100 million. Holland Venture Entrepreneurs Fund III is the ninth fund since Holland Venture’s foundation in 1981.

About Holland Venture
Holland Venture is one of the first independent private equity firms in the Netherlands. For more than 30 years, Holland Venture has been successfully and responsibly investing in promising small and medium-sized Dutch businesses with growth ambitions. With a clear investment strategy, Holland Venture anticipates long-term trends in attractive growth markets with a focus on the Healthcare and Technology sectors. Their experienced and dedicated investment team understands entrepreneurship. They aim for a transparent, supportive and professional relationship with the management teams, pursuing sustainable growth as a common goal. Holland Venture is supported by a broad network of successful entrepreneurs in Healthcare and Technology.

28
NOV
2016

Holland Venture invests in cloud & security specialist Avensus Netherlands BV

Amsterdam, November 28th, 2016 - Holland Venture invests in cloud and security specialist Avensus. The investment supports Avensus to achieve further growth in the financial and healthcare sector and to further develop its technological expertise in cloud and security.

Avensus was founded in 2000 and provides manageable and secure IT solutions that contribute to cost control, continuity, secure storage and data protection. Avensus has a loyal and appealing set of customers. For years now the top of the Dutch banking has been  benefiting from Avensus Crypto Services; the only Dutch security specialist with the highest accreditations to provide these services. By translating this expertise to other sectors, Avensus managed to acquire its current position as an IT partner for healthcare institutions. Protecting privacy-sensitive data is of vital importance for this sector and where it comes to the Managed Cloud Services, Avensus acts as directing and sourcing partner.

Holland Venture invests together with ICT-entrepreneur Abram Schermer. Mr. Schermer has a track record in IT and with his (hands-on) engagement he will commercially and strategically support and advise the Avensus management team. In 2010 Mr. Schermer, as founder, sold the system integrator Qwise successfully to Vision IT Group. Since 2015 he has worked as an independent investor and entrepreneur.

Ed Trautig CEO Avensus: "IT is essential for every organization; whether it comes to security, continuity or manageability. Avensus has set its focus in recent years on organizations in Healthcare and Financials. We know where the priority for these organisations lies and what they have to deal with in the future. Increasing regulation, block chain technology and robotics are emerging  in those sectors. To make sure that these companies are prepared for the future, that is what thrives Avensus every day. Not only from our High Grade Security expertise but also by linking this expertise to our Cloud Services,  so that every IT environment is implemented in a guaranteed safe way. By managing our customer’s IT-environment, we exactly know what the daily needs of these customers are. Therefor we have become an important IT partner for both the healthcare and the financial sector.

The cooperation with Holland Venture and Abram Schermer is a logical  next step for Avensus. These parties have had experience over many years  of growing (security) companies and Avensus is ready to grow. We believe that this partnership will help us in our ambition to acquire a leading position in our focus areas. "

"Security is a broad and increasing topic," according to Hubert Verbeek, managing partner of Holland Venture. "The market is large, dynamic and growing. The management of Avensus is experienced, has a proven track record and a clear vision on the security market. In combination with the IT knowledge in the field of Cloud Security and Encryption, and the growing market share within the healthcare sector, this investment fits perfectly within our investment strategy. "

ABOUT AVENSUS
Avensus is specialized in Cloud & Security Services and contributes to this directly by meeting business needs such as cost savings, flexibility and continuity. With our Secure Outsourcing Services, we are helping our customers not only through our own expertise but also through co-operation with leading IT partners. Unique is Avensus Crypto Services that mainly  supports the financial sector. These services are essential when it comes to protecting reputation and compliancy. Avensus is seen by the customer as ‘ the’ partner for manageable and reliable, secure IT solutions. - www.avensus.nl

ABOUT HOLLAND VENTURE
Holland Venture is one of the first independent private equity firms in the Netherlands and has been successfully and responsibly investing in promising small and medium-sized Dutch businesses with growth ambitions for more than 30 years. With a clear investment strategy, they anticipate long-term trends in attractive growth markets, focusing on the Healthcare and Technology sectors. An experienced and dedicated investment team knows entrepreneurship. They aim for an open, sustainable and professional relationship with management teams, with sustainable growth as a common goal. Holland Venture is supported by a broad network of successful entrepreneurs in Healthcare and Technology.


27
Sept
2016

Thanks to investment in Prolira BV, by Holland Venture and Health Innovations, early  detection of delirium will be possible.

27 SEPTEMBER 2016: With a cash injection, knowledge and a large network in healthcare, Holland Venture, Health Innovations and two business angels are helping to make Prolira’s Delirium Monitor the new international standard for detection of delirium.

Delirium, an acute state of confusion, is a serious medical condition. Delirium is common and particularly affects hospitalized elderly. It is an anxious experience that can lead to serious consequences, such as increased mortality risk, a longer stay in the hospital and long term cognitive impairment (dementia) and high health care costs. Patients who have experienced a delirium can often not go back to the life they had before and need to go to a nursing home. Research indicates, the sooner a delirium is treated the better. Early  detection helps to limit the impact on patients and saves costs.

Rutger van Merkerk, CEO of Prolira: "For millions of patients worldwide the improvement of delirium detection is important. This financial injection makes the development and production of a great health care innovation possible." Annemarie Willems, CCO of Prolira adds: "Hospitals in the Netherlands, Germany and Great Britain are ready to work with the Delirium Monitor. US hospitals have also shown interest, because we help tackle the growing delirium problem in a very practical way.”

Prolira develops a medical device, to detect delirium early and objectively. The company is a spin-off of the University Medical Center Utrecht (UMCU), and is based on clinical research led by neurologist-intensivist Prof. Dr. Arjen Slooter, who wants to improve the grip on delirium for everyone. Measurement of brain activity (EEG, a biomarker) proves to be effective and a good objective measure; 90% of the delirium cases are expected to be recognized. That is a great improvement over the current available, subjective, methods.

If detection is achieved at an early stage, intervention can be done quickly and appropriately, limiting negative consequences for patients. The Prolira Delirium Monitor measures brain signals from the patient through electrodes incorporated in a headband, that is easy to apply. A compact, portable monitor presents the results to care professionals. Prolira is the first and only party that makes delirium detection possible using EEG signals.

Hubert Verbeek, managing partner Holland Venture: "Delirium is a major problem for patients and hospitals. There is a great need for an easy solution that detects a delirium quickly and accurately. The Delirium Monitor contributes to a reduction of health care costs and an increase in the quality of care. We are excited to help Prolira make this monitor available as soon as possible."

Linze Dijkstra, managing partner Health Innovations: "We have been following UMCU’s delirium detection developments for several years. We are very impressed by the progress that has been made with the detection of delirium on the basis of EEG signals. The next step is to make this technology available to patients and hospitals as a product. Health Innovations is happy to play a role,  as this product will improve patient care.”

Prolira
In 2015 Prolira was founded by Rutger van Merkerk and Annemarie Willems to improve worldwide detection of delirium. The company is a spin-off of the University Medical Center Utrecht. Prolira is the first company in the world to bring an objective medical device for monitoring of delirium.

Holland Venture
Holland Venture is one of the first independent private equity firms in the Netherlands and has been successfully and responsibly investing in promising small and medium-sized Dutch businesses with growth ambitions for more than 30 years. With a clear investment strategy, they anticipate long-term trends in attractive growth markets, focusing on the Healthcare and Technology sectors. An experienced and dedicated investment team knows entrepreneurship. They aim for an open, sustainable and professional relationship with management teams, with sustainable growth as a common goal. Holland Venture is supported by a broad network of successful entrepreneurs in Healthcare and Technology.
 
Health Innovations
Since 2007 Health Innovations invests in Dutch companies aimed at improving health care, with a focus on early stage investments. In the past 10 years they invested in 20 Dutch companies who have contributed to improving care processes. With powerful entrepreneurship and a market-oriented approach, both quality gains and financial returns have achieved. Current and former portfolio companies are present in the field of services, software and medical technology. Shareholders in the funds of Health Innovations are ABN AMRO, Mediq and health insurers Achmea and VGZ. The Dutch Government supports Health Innovations with the Seed Capital scheme.

21
SEPT
2016

Holland Venture makes merger Qi ict and Onsight possible: Qsight IT is the largest Dutch player in the field of (cyber) security, networking and cloud.

21st of September 2016 - Holland Venture has played an active role in the merger from Qi ict Delft and Onsight Solutions from Arnhem. The investment contributes to the targeted buy-and-build strategy and confirms its expertise within the Dutch cyber security landscape.

"The merger of Qi ict and Onsight fits the strategy of both organizations to be the largest infrastructure specialist of the Netherlands," said Hubert Verbeek, managing partner Holland Venture. "The merger of these two parties, enables the merged entity to facilitate customers (both in the cloud and on premise) in their full security, networking and storage requirements. The early detection and adequate remedy of complex security threats is one of the key responsibilities of Qsight.

Martijn Hakstege, CEO of Qsight IT: "This cooperation is a 100% Dutch merger, which is an interesting fact in the context of privacy, legislation and data protection." In addition to Martijn Hakstege as CEO, the management team of Qsight IT consists of Rik van Winzum (commercial director), Arie Oosterlee (director services) and Luuk Boekhorst (CFO). Albert Klene, former CEO of Qi ict,  has been appointed as Director integration.

www.qsight.nl  


05
JuL
2016

INSPIRING HOLLAND VENTURE 'GROWTH SESSION' OF MENNO VAN DER MAREL (FOX-IT)

5th of July 2016- Cyber Security, the main topic during the second Holland Venture Growth Session. An issue Fox-IT plays a crucial role in with his 250 employees.

Menno van der Marel, CEO and co-founder, launched FOX IT together with his partner Ronald Prins in 1999. The company develops equipment for the protection of the Dutch State Secrets. Via digital ways they study integrity and fraud offenses and support the government and industry in keeping their digital environment safe. Fox-IT is often prominent in the news to explain and deepen in digital security issues. They also played an important role in various investigations into data leaks.

Fox-IT has experienced strong growth since 1999 and was acquired in 2015 by the British NCC Group. During the 'Growth Session' this development process of Fox-IT was the main topic, as well as the particular features that are related to such growth. Additionally Menno gave more insight into the world of cyber security. An inspiring story for the entrepreneurs of the Holland Venture investments.

During the Holland Venture Growth Sessions we invite a successful entrepreneur to share his or her experiences in a fast growing company with the management teams of our portfolio companies. These are interactive sessions with a focus on achieving growth by sharing experiences and tips-and-tricks in an informal setting.

27
jun
2016

Autheos receives substantial investment for innovative video syndication network

American VC-veteran Guy Bradley and Holland Venture invest in Amsterdam-based startup Autheos

Amsterdam, 27 june 2016 – Investment firm Holland Venture and Guy Bradley co-invest in Autheos. Autheos offers a many-to-many syndication network for brand and product videos. With this investment, Autheos will focus on rapidly expanding its team and international footprint.

The market for product video distribution has traditionally been dominated by Content Distribution Platforms. These platforms are often costly, complex to use and time consuming to implement and integrate. Autheos has automated this process and offers its clients a simple solution to manage all brand and product videos via a single platform. This solution allows global brands to quickly and easily deliver their product videos to e-commerce platforms worldwide, in the appropriate format. Within the Benelux region, Autheos has built a dominant position of over 70% market share, counting top e-commerce sites such as Bol.com, Wehkamp, Nextail and ECI as clients. “With our central and easy to manage worldwide network, our clients can increase their profits. Research proves that brand and product videos improve sales conversion rates on e-commerce sites, by up to 64%. Our clients also love our network for the time and cost efficiencies that it affords their organizations. We work in a constant feedback and product iteration loop to continuously improve the client experience, and this additional financing will allow us to both speed that process and broaden our market share internationally.” according to Pyke van Dieren, CEO at Autheos.

International expansion
Following this investment, Autheos will be actively supported and advised by Guy Bradley and Holland Venture. Both parties have a deep international network that will facilitate Autheos’  expansion efforts. This August, the team will be further enhanced by Christina Caljé, the current COO at Peerby and former Executive Director at Goldman Sachs. A practical expert in lean startup methodology, Caljé radically accelerated product development and revenue growth for Peerby, is a valued mentor for several startups, and will reinforce lean startup practices at Autheos as co-founder and COO. Angel investor Guy Bradley has a lot of experience with investing in rapidly growing startups and will advise Autheos on their international expansion and further development of their product. The financial investment and expansion of the leadership team will support Autheos in this next phase of growth. Niels van Aalten, partner at Holland Venture, states the following: “Autheos solves a tangible problem for global brands and has a very scalable proposition. We’re very excited about supporting Autheos in their international growth together with VC-veteran Guy Bradley.”

About Autheos  
Since 2012 Autheos delivers brand and product videos to the e-commerce market with its many-to-many syndication network. With a market share of more than 70% in the Benelux Autheos will now focus on further expanding internationally. The first step in this process was taken by offering their video syndication network for free, enabling brands and e-commerce platforms all over the world to join the Autheos network for free. Autheos was a finalist in the I-COM Data Venture Challenge. https://www.autheos.com

Additional resources:
https://www.videobrewery.com/blog/18-video-marketing-statistics
https://www.crunchbase.com/person/guy-bradley-2#/entity
https://www.i-com.org/dvc-overview-2016/

13
june
2016

Holland Venture and BOM invest in CytoSMART: digital microscopic imaging in the cloud

Amsterdam/Tilburg, 13 June 2016 - Private equity firm Holland Venture and the Brabant Development Agency (BOM) are together investing in CytoSMART Technologies. Founded in 2012 under the name CytoMATE, CytoSMART is a spin-off of Eindhoven University of Technology (TU/e). The company develops smart devices for use in laboratories around the world.  The first product, CytoSMARTTM Lux, is a small digital microscope that can be used to continually monitor cell cultures in a CO2 incubator and send the images straight to the cloud, where they can then be examined by an analysis tool.

The current cell culture process is a time-consuming, error-sensitive process, and throughout the process is a black box for lab technicians. During the cell culture, only a brief visual inspection is made. Actual growth can only be measured afterwards. This is because the cells have to be taken out of the incubator, which has a detrimental impact on the optimum conditions in the incubator, potentially influencing the results. In this way, the lab technician only finds out at the end of the process whether the culture has been a success or not. Using the CytoSMART device, the cell culture can be monitored in real time, making it possible to make adjustments throughout the process. Furthermore, CytoSMART has developed a number of smart software tools that can perform a more accurate analysis of the cell culture.

“The lack of real-time data on a cell culture is a problem that all laboratories face. Our product offers a solution to this and makes it possible to monitor and analyze this information using any device. To continue to innovate, we will have to further expand our operation and focus on product development. Having Holland Venture and BOM on board will enable us to do just that. They understand what innovative medtech businesses need to realize their ambitions,” says Joffry Maltha, CEO of CytoSMART.

Ewout Prins, a managing partner of Holland Venture, is pleased with the investment: “CytoSMART has an innovative technology which can add significant value in the medtech sector. The products and software tools of CytoSMART enable biomedical research to be completed more quickly, more efficiently and more accurately. This makes the business a very good match for the investment focus of our health care innovation fund. We look forward to actively supporting the growth of CytoSMART as it moves to the next level.”

“CytoSMART has developed a unique platform technology for real-time imaging systems for use in laboratories. The product developments of CytoSMART prove that the medtech ecosystem in Brabant province works and holds even further potential. BOM will make an active contribution to the further development and growth of CytoSMART and to this very promising industry,” says Miriam Dragstra, Director of BOM Capital.

About Holland Venture
Holland Venture was founded in 1981, making it one of the first independent private equity firms in the Netherlands. In the past 30 years, we have successfully and responsibly invested in more than 120 small and medium-sized Dutch businesses. With a clear investment strategy, we are active in the attractive growth markets of Healthcare and Technology.  Our experienced and committed investment team knows what entrepreneurship is, and they aim for an open, sustainable and professional relationship with the management teams of the businesses we invest in, with the common goal of achieving growth. Holland Venture is supported by a broad-based network of successful entrepreneurs in the Healthcare and Technology sectors. www.hollandventure.com

About the Brabant Development Agency (BOM)
Innovative solutions to social issues are the driving force of economic development. BOM supports business owners in a variety of ways in order to help the economy of Brabant province grow. BOM invests venture capital in innovative businesses in the start-up and growth phases, we forge collaborative links between businesses, we attract foreign businesses, and we develop and redevelop industrial sites. To date, BOM has invested in 16 businesses in the life sciences and medtech sectors. BOM is based in Tilburg and currently has a workforce of around 90 people.


12
FEb
2016

Humeca officially launches sister company Humeca, Inc. in the USA

The launch follows a steady growth in demand and supply of their products worldwide and enables Humeca to expand their distribution network in the United States. The skin grafting products are life-saving for the treatment of burn victims. Humeca’s dedicated Sales Manager, Alison Willox is already seeing positive and growing interest from hospitals and burn centers throughout the country.

Founded in 1981, Humeca B.V. is a company that develops and markets innovative products particular in the field of burn surgery. It is the one stop shop for burn doctors. With all products FDA registered and readily available, Humeca aims to bring a unique and personal service. With their products they provide medical experts with materials and equipment for optimum treatment of their patients. Humeca is doing business successfully in over 70 countries. In the US, there is a continual need for specialist products for the treatment of burns. By establishing Humeca, Inc. the company enables the supply of their services directly to hospitals who treat many of the 40,000* burn victims who are admitted every year. Humeca, Inc. provide a selection of cordless, battery operated dermatomes, a wide range of dermatome blades, skin meshers and mesh graft carriers and are also proud to be able to offer the revolutionary MEEK Micrografting machine.

Bringing the MEEK technique home
The MEEK technique was originally described by Dr. Cicero Parker Meek from the University of South Carolina Aiken (USCA), USA in 1958 where postage stamp autografts were obtained and expanded using double pleated gauzes with a nine fold expansion. However, this original technique required too much skill and it became eclipsed by the introduction of mesh skin grafts by Tanner et al. in 1964 and was eventually discontinued. In the early 1990’s two surgeons from the Red Cross Hospital, Beverwijk, in The Netherlands approached Humeca and asked for help in re-introducing a modified meek technique. After much engineering and re-design the modified meek technique was finalized and released in 1993. Humeca, Inc are excited to “bringing home” and introduce the life-saving modified MEEK technique to the USA.

Chairman and President Mr. Arnoud Van Velzen said: “The establishment of Humeca, Inc. is the consequence of many US enquiries regarding our Humeca products. We are proud that our life-saving equipment is now accessible to more than 120 burn centers in the US.”


08
dec
2015

Holland Venture provides substantial investment to marketing technology company Relay42

Amsterdam, December 8th 2015 – Holland Venture and a former Board Executive of Booking.com have invested several millions of euros in the Dutch data management specialist Relay42. Marketers use Relay42’s innovative data management platform to coordinate the customer journey across all marketing channels. Based on real-time data insights from marketing channels and machine learning, enterprises are empowered to personalize their marketing messages to consumers. Relay42 is market leader in the Netherlands and has recently appointed a team in the UK. The series A investment will accelerate Relay42’s international growth.

Tomas Salfischberger, CEO of Relay42 says ‘we are ready for the next phase. Relay42 became market leader in the Netherlands as a serious alternative for marketing cloud providers such as Adobe, IBM and Oracle. Instead of an expensive marketing cloud implementation, enterprises prefer to be free in choosing their own combination of marketing technology providers. With Relay42’s data management platform, clients can retain their independence and are empowered to work with the latest, best-in-class marketing technologies. Additionally, it has become increasingly important for enterprises to assert control over their customer data. More than 30 major European enterprises are currently using our platform, realizing an average conversion increase between 20 to 30 percent. This translates into increased revenues. We are looking forward to expanding in Europe and helping clients to make their marketing more data-driven.’

International growth
In addition to providing growth capital, Holland Venture will actively support and advise Relay42’s management. Moreover, Holland Venture will open up their international network to support Relay42’s international expansion. Niels van Aalten, partner at Holland Venture: 'Relay42 provides a unique solution for marketers, combining the latest in big data and marketing. With this investment, we can accelerate the international growth of the company. I am looking forward to working with Relay42’s talented team.'

Supervisory Board
Marc Duijndam (ex-Google, ex-LinkedIn, current CEO at Funda), Maurice Pothof (ex-Google, current angel investor) and Niels van Aalten (Partner at Holland Venture) will be appointed as the Supervisory Board of Relay42. Their large international network will be key for the global expansion of Relay42.

About Relay42
Relay42 is a data management specialist. Founded in 2011, its innovative platform aims to help enterprises achieve better results with both online- and offline marketing. Relay42’s platform is integrated with an ecosystem of best-in-class marketing technology providers. With the centralized and immediate analysis of data, clients can effectively personalize marketing messages and activate them real-time across all channels. This allows for average conversion increase of 20 to 30 percent. Relay42 is currently used by more than 30 major enterprises such as KLM, Thomas Cook, BMW, Foot Locker, Liberty Global and Nuon (Vattenhal). For more information, please visit www.Relay42.com.

About Holland Venture
Holland Venture is one of the first independent private equity firms in the Netherlands. For more than 30 years, Holland Venture has successfully and responsibly invested in promising small and medium-sized Dutch businesses with growth ambitions. With a clear investment strategy, Holland Venture anticipates long-term trends in attractive growth markets, focusing on the Healthcare and Technology sectors. Our experienced and dedicated investment team knows what entrepreneurship is. Holland Venture aims for an open, sustainable and professional relationship with the management teams of portfolio companies, with the common goal of achieving growth. Holland Venture is supported by a broad network of successful entrepreneurs in Healthcare and Technology. For more information, please visit www.hollandventure.com.


03
dec
2015

Roelant Prins (Adyen) shares his experiences at Holland Venture’s first Growth Session

Holland Venture’s first Growth Session, with guest speaker Roelant Prins – CCO of Adyen – was a great success. In an interactive session with entrepreneurs and the Holland Venture team participating, Roelant shared his experiences in managing a fast growing organization and setting up foreign operations.

Adyen is a Payment Service Provider that provides both online and offline payment services for shops, web shops and market places. Since the start in 2006 Adyen has grown rapidly to a multinational company with  offices in 13 countries, over 340 employees active on six continents.

Adyen processes approximately EUR 40 billion in payments annually for various clients including Facebook, Spotify and Groupon. In 2015 Adyen expects to make a turnover of EUR 320 million. Adyen has received several  equity investments.  In its most recent investment round it saw the investment fund Iconiq capital join the shareholder base in a transaction valuing Adyen at more than EUR 2 billion.

As CCO, Roelant Prins is responsible for the commercial activities at Adyen. He talked about the rapid growth of the company and the way the organization deals with this growth. During the Growth Session he discussed interesting subjects such as scaling up internationally, product development, organization and culture, maintaining the startup mentality, funding strategy and his own experiences in Silicon Valley.

The Growth Session was received enthusiastically by all participants and the extensive interaction inspired the entrepreneurs of the Holland Venture portfolio companies. Roelant’s experiences and hands-on tips of were considered very valuable and helpful for the entrepreneurs in realizing their own foreign growth strategies.

 

During the Holland Venture Growth Sessions we invite a successful entrepreneur to share his or her experiences in a fast growing company with the management teams of our portfolio companies. These are interactive sessions with a focus on achieving growth by sharing experiences and tips-and-tricks in an informal setting.

A next Growth Session will probably take place in February 2016.


26
nov
2015

Second financing round for innovative patient ventilation device of Ventinova

Eindhoven, 26 November 2015 - Ventinova Medical B.V. closed a second financing round with existing shareholders Holland Venture and BOM Capital and new investor InvestInFuture and a group of Informal Investors. Ventinova develops and sells innovative medical devices in the field of airway management and patient ventilation. The company will use the invested capital for the market launch of its newly developed automated ventilator and for expansion of the organization.

Ventinova, founded in 2013, developed the patented expiratory ventilation assistance technology, better known as EVA®. Current products Ventrain® and Cricath® are sold in over 20 countries. Thereby, the EVA® technology has already entered many hospitals. Now to be followed by the EVA® device and the CNB tube.

The new investment enables various studies in collaboration with the University Hospital of Freiburg (Germany), Henri Mondor (Paris, France) and Yale (New Haven, USA). The money enables an expansion of the team and allows active presence at international conferences as Euroanaesthesia 2016 in London and American Society of Anesthesiologists in Chicago.

In addition to the millions of Venture Capital, Ventinova had recently received an EU grant of EUR 1,9 million. The top 3 ranking out of the 269 grant applications confirms the importance and quality of the development and market plans.

Dirk van Asseldonk, CEO of Ventinova Medical B.V., says the following about the successful financing round: “I am very pleased with the investment of the existing and new investors. They understand the needs of innovative start-ups active in the healthcare sector and help them to realize their ambitions. I look forward to the market introduction of the EVA® device and the CNB tube.”

Edgard Creemers, CEO of InvestInFuture is confident about the investment: "Dirk van Asseldonk is an energetic and professional entrepreneur who will bring this game changing product to the hospital".

6
okt
2015

Holland Venture realized an excellent return on the sale of Bureau PENG

Amsterdam October 6, 2015 - Last week Holland Venture signed the documents relating to the acquisition of Bureau PENG by its current director Martijn van Kraaij and a Dutch family office.

Bureau PENG offers flexible staffing solutions to municipalities, credit banks, financial institutions and enterprises. The company has a history of providing debt counseling specialists and budget management specialists. In addition to the excellent in-dept knowledge and the high level of productivity, mainly the coaching skills of the PENG professionals are unique.


Growth in sales and profits
In 2013, Holland Venture joined as a shareholder by providing growth capital. Holland Venture actively supported Bureau PENG in the strategic growth and development of the company. Since the start Bureau PENG achieved excellent results. Bureau PENG expanded its services with client managers Participation & Income and WMO consultants. Due to this expansion and the growth of existing services the workforce has grown from 20 specialists to more than 80 specialists within two years.

Excellent return
Hubert Verbeek, managing partner of Holland Venture: "We have achieved a good return on this transaction. Nevertheless, there is still plenty of growth potential for Bureau PENG. We wish the new shareholders a successful future."

24
sep
2015

Substantial EU subsidy for revolutionary life-saving Expiratory Ventilation Assistance (EVA) technology

Eindhoven 24 September 2015 - Ventinova Medical BV, a company that develops and sells innovating medical products in the field of anaesthesiology, together with three partners, has received an EU subsidy in the amount of EUR 1.9 million. Selected third from the 269 applications, this is a valuable medical quality mark for the life-saving EVA technology and the products that follow from it. This subsidy will be used to finance the market launch of the automated version of the current manual ventilation device Ventrain®.

Ventinova, established in 2013, has developed the “Expiratory Ventilation Assistance technology”, better known as EVA®. The technology has been optimised for a completely or partially blocked airway, in which the advantages of various conventional technologies are combined. What makes this ventilation method so unique is that it enables to ventilate through an extremely thin tube. And the expiration is actively controlled instead of the current passive expiration. This new method leads to a sharp reduction in the number of complications and a considerably higher chance of survival in the case of resuscitation. Because of the actively controlled expiration and thin catheter, the new EVA ventilator can open new possibilities for surgical treatment in combination with ventilation.

Automated version of Ventrain®
The current manually operated product Ventrain® is intended for extremely specific, highly life-threatening situations. This a limited application range, but a good way to introduce the ventilation method EVA® within the hospitals. “Now that hospitals are familiar with EVA® through the experience with Ventrain®, the time has come to introduce the automated product. Its scope of application is much broader, for example scheduled difficult airway surgery. Our aim is to make EVA® the standard ventilation method in various fields of surgery worldwide. The granted EU subsidy is a valuable external medical quality mark that supports our ambition”, says Dirk van Asseldonk, CEO of Ventinova.

Large network of key opinion leaders
Ventinova received the EU subsidy in cooperation with the universities in Freiburg and Paris. They, next to academic instutes in London, Dresden, Maastricht, Cornell and Yale, will support Ventinova in carrying out various pre- and post-market studies. “EVA has the promise to become a major breakthrough in mechanical ventilation both in surgical and intensive care patients” says Prof. Dr. Marcelo Gama de Abreu M.D. Head of Translational Research in Anaesthesiology and Intensive Care medicine at the Dresden University in Germany and member of Ventinova’s Scientific Advisory Board.

Growth strategy
The first results with EVA® are very promising. The current products Ventrain and Cricath are now being sold in more than 20 countries around the world. The method is unique and so there are no immediate competitors. Together with the current investors Holland Venture and BOM Capital, Ventinova strives to launch the automated product mid-2016. In addition to current markets such as the Netherlands, the UK, China and Australia, it will focus on new export countries such as USA, Canada and Brazil. In addition, major investments are being made in the clinical validation of the new device by means of various multi-centre patient studies.


20
aug
2015

Holland Venture starts technology fund

Amsterdam, August 20, 2015 - Holland Venture started a new fund for young, fast-growing technology companies. Holland Venture Technology Fund focuses on six specific areas: mobile internet, software in the cloud, internet-of-things, cyber security, big data solutions and automation of knowledge work.

Holland Venture Technology Fund (HVTF) is the eighth fund of Holland Venture. The fund management of this fund has been reinforced with Niels van Aalten, who has extensive experience as an angel investor and advisor in the areas of business growth and the realisation of exits. In the coming years, the fund would like to realise approximately 10 investments within the technology sector. The Dutch government supports the fund with a seed capital initiative, an incentive arrangement provided by the Ministry of Economics Affairs, Agriculture and Innovation (EAI).

Niels van Aalten: "We are looking for innovative companies with proven products / services, and a strong and well-balanced management team. We like to invest in companies with a distinctive market and a scalable business model that can grow into global players."

Hands-on support
These companies can expect a hands-on investor that provides both growth capital and its network expertise and commitment to facilitate growth. In close collaboration with company management a growth plan will be constructed. The Holland Venture team provides hands-on support and practical tools to professionalize the company in the field of marketing, HR, legal, and financial administration. This gives business owners the opportunity to focus on developing their business.

Network of IT entrepreneurs
Holland Venture is supported by a network of successful IT entrepreneurs like Cees Links (ceo Fast 50 winner GreenPeak Technologies, inventor of wifi networks), Ronald Prins and Menno van de Marel (founders Fox-IT) and Marc Duijndam (former Google, former Linkedin, current CEO Funda). They will assist in tracking and supporting of investments and hence provide significant added value.

Holland Venture expects that these entrepreneurs will be involved in the generation of leads, evaluating investment propositions, and will also be active in guiding rapidly growing portfolio companies.

HOLLAND VENTURE
Holland Venture is one of the first independent private equity firms in the Netherlands. They have been successfully and responsibly investing in promising small and medium-sized Dutch businesses with growth ambitions for more than 30 years. With a clear investment strategy, they anticipate long-term trends in attractive growth markets, focusing on the Healthcare and Technology sectors. Their experienced and dedicated investment team knows what entrepreneurship is. They aim for an open, sustainable and professional relationship with the management teams, with sustainable growth as a common goal. Holland Venture is supported by a broad network of successful entrepreneurs in Healthcare and Technology.

19
jun
2015

Second financing round for SigmaScreening with existing and new shareholders

Amsterdam, 19 June 2015 - SigmaScreening B.V. has successfully concluded a new  financing round with existing shareholders, including Holland Venture and the new shareholder De Friesland Zorgverzekeraar (DFZ). SigmaScreening, a spinoff of the Academic Medical Centre of Amsterdam, has developed an innovative  mammography product based on an AMC invention that effectively prevents unnecessary pain during breast cancer screening. SigmaScreening will use the funds to offer its product, which is used successfully by the AMC, to other hospitals and screening centers in the Netherlands and the rest of the world.

Every year, 150 million women around the world are tested for breast cancer. This is nearly one and a half million women between the ages of 50 and 75 in the Netherlands alone. After 45 years of breast screening, SigmaScreening’s solution represents an important step in addressing over-compression, significantly reducing pain. What makes this new product so unique is that it takes into account individual breast size and the  compression needed for a clear mammogram. This  both benefits women and optimises image quality. SigmaScreening employs professionals in the fields of radiology, mammography, biomedical physics and medical IT. For technical development and production, it works with leading manufacturing and engineering organisations such as Claymount Assemblies and Demcon.

Adapting existing and integrating new equipment
Market Research shows that there is a worldwide need for the Sensitive Smart Paddle. This product will be launched on the market in late 2015, so that existing systems can be equipped with this product. SigmaScreening is  also working to integrate this new technology into newly built systems. The DFZ investment will accelerate the market introduction of these products.

Director Ivo Aarninkhof of SigmaScreening has already seen the effectiveness of this technology confirmed in various countries, hospitals, screening centers and mammography equipment manufacturers. "This innovative mammography function helps to significantly reduce pain during breast screening by offering much more sensitive compression adapted to individual women. Based on current technologies, this innovative product will be accepted by the market much more readily than if it were a radically new technology.”


04
feb
2015

Unique healthcare communication platform receives strategic investment

The investment of Holland Venture and InnovationQuarter in IQ Messenger – the new communication platform within the healthcare sector  –  is officially sealed today by Drechtsteden director Richard Korteland and administrator of Economic Affairs Jasper Mos. The innovative platform is the link between a wide variety of new and existing communication and alarm systems. The use of IQ Messenger within healthcare improves the quality and efficiency and contributes to cost reduction. Paul Vos, CEO IQ Messenger Holding BV, is proud of the innovation and enthusiastic about the financial boost: “This investment  enables IQ Messenger to accelerate her growth and increase her impact.”

Innovative solution  allows healthcare organizations to be “in control”
IQ Messenger combines existing communication solutions within healthcare in a new, innovative way. The platform is the link between a wide variety of new and existing communication and alarm systems. It includes features  such as alarm and video surveillance via smartphone and tablet. Without any producer preference and equipped with unique and uniform applications for administration, reporting and monitoring, the platform is able to transform non-coherent systems in one smart and powerful solution. Thanks to  a Medical Class certification IQ Messenger is applicable for medical  alarms.

The increasing demand for care creates pressure on the healthcare budget. Care providers strive to focus on providing high quality care as efficiently as possible. IQ Messenger improves both communication and quality of care and simultaneously reduces costs. The digital platform with many smart integrations gives utmost priority to healthcare organizations and their working processes. Thanks to the unprecedented flexibility, the ease of management and  broad range of integrations, healthcare organizations are now “in control”. IQ Messenger is already used by over hundred national and international healthcare organizations since the founding of the company.

Investors opting for innovation 
Holland Venture and InnovationQuarter share the excitement about IQ Messenger as an integrated software platform for nurse call, alarm, personal security, reporting and communication within the healthcare sector. With her brand independent platform IQ Messenger offers healthcare organizations the opportunity to improve the quality of care and reduce costs,” says Ewout Prins, managing partner Holland Venture. “We have great confidence in the entrepreneur Paul Vos and his team and we gladly support the further development and commercial expansion of this company.”

IQ Messenger enables healthcare organizations to provide their employees faster and better information about the needed care per patient. “The investment in IQ Messenger perfectly fits our fund focus: an innovative company addressing and solving important social issues” says Francis Flu-Quint, Head of Capital at InnovationQuarter.

As committed investors Holland Venture and InnovationQuarter will remain involved in continuous scaling and professionalization of IQ Messenger.

03
oct
2014

Holland Venture and management sell their shares in De Ridder to Bunzl Plc

Holland Venture and management sell their shares in De Ridder to Bunzl Plc
Earlier this week, the shareholders of De Ridder signed the documents relating to the acquisition of De Ridder by Bunzl Plc. The management of De Ridder will continue to be involved with the company after the acquisition.

For over 25 years, De Ridder is a leading supplier of non-food disposable products to the Dutch detention market which includes prisoners, asylum seekers and psychiatric patients residing in a detention setting. Furthermore the company supplies the police and forensic institutes with products related to forensic investigations.

Bunzl Plc is a leading specialist distribution group with operations in 27 countries across four continents. The group supplies a wide range of consumable products to various customer markets including grocery, foodservice, cleaning and hygiene, safety, non-food retail and healthcare. Bunzl Plc is a FTSE100 company listed on the London Stock Exchange.

Since 2012 Holland Venture has been a shareholder in De Ridder. The investor actively supported management in the strategic development of the company. During this period, De Ridder has been able to improve her market position nationally as well as internationally. This has resulted in the company becoming the market leader in her home market of The Netherlands. With this transaction Holland Venture realized an excellent return on its investment.

15
apr
2014

Investment Holland Venture accelerates growth strategy of Humeca

The company from Enschede is active in the field of product development, assembly and worldwide sale of medical instruments for the treatment of burns and skin grafts. The investment enables Humeca to further professionalize the organization and to realize its growth ambitions.

Humeca was founded in 1981. The upcoming retirement of Humeca’s founders led to the sale of the organization by Holland Venture in cooperation with Arnoud van Velzen. Arnoud van Velzen (50) has been active in the medical business since 1985. He gained both national and international experience in the field of product development and the international marketing of medical products. Arnoud van Velzen has a background as a surgical assistant, he gained extensive experience in business developments within orthopedics and surgery.

Humeca develops and sells skin grafting products based on the MEEK technique for the treatment of burn patients. In cooperation with the burn center of the Red Cross Hospital Beverwijk, Humeca developed skin grafting products, like dermatomes, dermatome blades and MEEK equipment. With the MEEK technique the surface of the removed skin could be significantly increased with relatively little impact on the wound healing. Humeca’s products are sold worldwide in more then 66 countries via 47 specialized distributors.
Arnoud van Velzen is very enthusiastic about his new role as managing director of Humeca. “Humeca is a successful company with a long history in the field of skin grafts. My goal is to professionalize the company, generate more brand awareness and realize more global sales. I am convinced that Holland Venture will support Humeca in realizing the existing growth opportunities.”

Hubert Verbeek, managing Partner Holland Venture, welcomes the new investment: “Humeca holds a technology that offers a significant improvement in the quality of burn treatment. The company has a substantial growth potential. We see geographic expansion opportunities in countries like America, Russia, India, China, Iraq and Brazil. Product development in new markets such as plastic surgery is also possible.”

12
mar
2014

Holland Venture and Dolfin Capital invest in IPPZ

Investment companies Holland Venture and Dolfin Capital invest in IPPZ , a successful developer of e-health products for the mental healthcare sector. In IPPZ’s vision e-health enables the optimal balance between face-to-face contact and remote care. The investment enables IPPZ to realize its growth ambitions: to make e-health available to any practitioner and provide patients the opportunity to organize their own healthcare.

Joris Moolenaar, founder and director of IPPZ states: "In 2009 we started developing cloud based e-health software. Since then we have experienced considerable growth . Our new product Karify is an online ecosystem that offers practitioners and patients a wide range of e-health applications. This allows the practitioner to better support his patient relationships and enhance treatment. To continue to serve our existing and new customers well, we will expand and further professionalize our organization. The involvement of Holland Venture and Dolfin Capital allows us do this. With great anticipation we look forward to working with our new partners."

Ewout Prins , managing partner Holland Venture, is enthusiastic about the investment: "IPPZ is an innovative company with a distinctive product. It enables healthcare providers to develop blended care programs in a simple and flexible way, facilitating easy integration with the conventional care process. Blended care programs give substance to two important needs in the sector: effectiveness and efficiency. Additionally, it provides care consumers more flexibility in communicating with their practitioners. With this investment Holland Venture and Dolfin Capital support better care at lower costs."

About IPPZ
IPPZ was founded in 2009 by Joris Moolenaar and Frank Kraaijeveld, from a shared vision that simple, scalable e-health solutions, should be available for mental healthcare institutions, hospitals and general practitioners .The company is located in Utrecht (The Netherlands) and has 17 employees. IPPZ works closely with many reputable mental healthcare institutions and health centers, such as GGZ Centraal, Arkin, Altrecht and SAG (Health Foundation Amsterdam). With the products myTherapy and Karify IPPZ enables them to efficiently deliver effective care treatments with e-health.

07
mar
2014

Holland Venture invests in an innovative mammography product

Private Equity firm Holland Venture invests in cooperation with Participatiemaatschappij Oost-Nederland (PPM Oost), Life Sciences Fund Amsterdam and Demcon in the medical company SigmaScreening B.V.. SigmaScreening, a spin-off of the Academic Medical Centre in Amsterdam, has developed an innovative mammography product based on an AMC invention that effectively prevents unnecessary pain during breast cancer screening. SigmaScreening will use the funds to offer its product, which is successfully used by the AMC, to other hospitals and screening centres in the Netherlands and the rest of the world.

Every year, 150 million women around the world are tested for breast cancer. This is nearly one and a half million women aged between 50 and 75 in the Netherlands alone. Pain suffered during screening is reason for one in five women to decide against having a mammography. After 45 years of breast screening, SigmaScreening´s solution represents an important step in addressing overcompression, significantly reducing pain. Uniquely, the new product takes into account individual breast size and the compression needed for a clear mammogram. This will benefit both women and optimize image quality.
SigmaScreening employs professionals in the field of radiology, mammography, biomedical physics and medical IT. For its technical development and production it works with leading Dutch organisations such as Claymount Assemblies and Demcon. According to SigmaScreening, there is a global need for the solution it offers, opening up a huge sales market. Entering the final phase before the market introduction, SigmaScreening is winding up the certification and development phase and setting up the marketing & sales activities in the Netherlands.

Director Ivo Aarninkhof of SigmaScreening expects a great deal from the innovation: “This innovative mammography function helps to significantly reduce pain during breast screening by offering much more sensitive compression adapted to individual women. Based on current technologies, this innovative product will be accepted by the market much faster than if this was a radically new technology.”

Ewout Prins, managing partner Holland Venture, welcomes the new investment: “SigmaScreening holds an innovative technology which helps to significantly reduce pain during breast screening. This will rise the attendance at breast screening and consequently possible breast cancer will be detected at an earlier stage. Early diagnosis improves the quality of care and reduces the cost of treatments. SigmaScreening perfectly fits the strategy of our Health Innovation Fund. We are looking forward to support SigmaScreening actively in its growth to the next phase.”

25
nov
2013

Holland Venture invests in full-service internet agency Virtual Affairs

Investment supports international growth ambitions
Private equity firm Holland Venture invests in full-service internet agency Virtual Affairs, a digital solution provider in the financial sector. The investment enables Virtual Affairs to realize its international ambitions. Members of the management team and some key-employees of the company also acquired (extra) shares in Virtual Affairs.

Holland Venture acquired a significant minority share in Virtual Affairs, the Company supports banks and insurance companies in the design, implementation and exploitation of their digital channels. The Netherlands has a world-leading position in online banking and insurance. The investment and participation of Holland Venture enables Virtual Affairs to seize further international growth by exploiting solutions developed in the Netherlands.

International demand
“Our company is evolving rapidly. We serve a large number of customers in the Netherlands but also internationally people ask for our expertise and solutions” according to Sijbrand Tieleman, CEO Virtual Affairs. “In Holland Venture we found a financial partner giving strategic assistance and supporting the company’s growth ambitions. I look forward to our cooperation, says Tieleman.

Distinct vision
Ewout Prins, managing partner Holland Venture, is confident about the future of the company: “Virtual affairs  capitalizes on the digitization of the financial sector. The company has a distinct market vision which it translate into interesting propositions for banks and insurance companies. We see ample growth opportunities and are convinced Virtual Affairs and its ambitious team are able to grasp these chances, Holland Venture is eager to support them.

Virtual Affairs
Virtual affairs, established in 1997, is a company advising clients on their digital strategy and creating digital solutions used by banks and insurance companies. Virtual Affairs employs over 130 employees, situated in offices in Amsterdam (HQ), Rotterdam and Sofia (Bulgaria). Virtual Affairs assist clients in finding and establishing new sales and service channels, refining accessibility of complex (financial) information and improving businesses. The internet agency works for a large number of reputable firms, including Aegon, Knab, Nationale Nederlanden, Syntrus Achmea, Rabobank en ABN Amro.

09
aug
2013

Start-up Ventinova attracts growth capital

Holland Venture and Brabantse Ontwikkelings Maatschappij (BOM Capital) jointly invest EUR 2 million in Ventinova; a start-up developing innovative patient ventilation equipment. The company markets the Ventrain a single-use ventilation device specifically designed for use in operating rooms, ambulances and intensive care. The investment by Holland Venture and BOM capital enables Ventinova to further develop its Ventrain and accelerate international expansion.

Ventinova is a spin-off of Dolphys Medical and was founded in 2013. Dolphys Medical , a TU/e spin-of, developed the Ventrain in close collaboration with the University Hospital Maastricht. The company is based in Eindhoven and employs 6 people.

Ventrain is a single-use ventilation device specifically designed for emergency situations. It provides adequate ventilation even in case of a completely obstructed upper airway. A revolutionary and patented device, Ventrain is able not only to inject oxygen into a patient, but also to actively suck out the respiratory gases through a very small tube. Ventrain is now being marketed in 23 countries by 13 distribution partners. Although Ventrain is not yet FDA approved, it is the only product advised for emergency ventilation in the USA edited handbook “Benumof and Hagberg’s airway management”. The company expects to enter the US market in 2014.

The investment will enable Ventinova to develop a new generation of ventilation equipment. This new generation of products will not only be used in emergency situations but also during elective procedures. It is expected that the Ventinova solutions offer significant advantages over the existing ventilation equipment on the market. Furthermore the funding is to be used for expansion of  Ventinova’ s distribution network.
Dirk van Asseldonk, CEO and founder of Ventinova: “I am very pleased with the investment of Holland Venture and BOM Capital. They understand the needs of young innovative start-ups active in the healthcare sector and help them to realize their ambitions. I look forward to our future cooperation.”

Ewout Prins, managing partner of Holland Venture, welcomes the new investment: “Ventinova holds a truly ground-breaking technology that offers a significant improvement in quality of patient ventilation . The increase in quality leads to a decrease in complications, resulting in improved outcomes and lower healthcare costs. Ventinova perfectly fits the strategy of our Healthcare innovation fund.”  

Mariëtte van der Velden-Roesink, investment manager of BOM Capital comments: “We believe Dirk van Asseldonk is a true entrepreneur that is capable of realizing the full potential of this life-saving technology. Ventinova is a prime example of a start-up active in the Noord-Brabant life science & health sector, contributing to the development of the region.”

05
mar
2013

Holland Venture invests in forensic supplier De Ridder

Holland venture invests in De Ridder, a company offering a wide range of products in the fields of hygiene and care, cooling elements, gelpacks, tapes, and non-woven products. The investment of Holland Venture enables De Ridder to seize further national and international growth opportunities.

Established in 1981, De Ridder has grown from a distributor of double sided tape and non-woven products to a full-service supplier which offers added value through a wide range of products and customer specific product development. Its products are mainly supplied to judicial enterprises, as well as industrial and pharmaceutical  companies. Within the next years, De Ridder aims to strengthen her focus on the judicial markets for national and international customers.  In addition  De Ridder will offer her products to the medical disposable segment. Within these focus markets, growth  will be  pursued organically as well as via acquisitions.

Stijn Vos, General Manager: “De Ridder is a successful company with a long history, loyal employees and a valuable clientele. In The Netherlands we are market leader in several niches and we see many possibilities for growth. Holland Venture is a professional partner for growth companies and offers experience and a large network. We are convinced that the Holland Venture team will assist us in realising  the existing growth opportunities.”
Hans Baars, Commercial Director: “De Ridder has a strong customer focus.  We continuously develop our product portfolio in consultation with our customers, for example in the promising niches of DNA-free and sterile sets. Based on our broad experience in the Netherlands, we have developed a thorough understanding of customer needs in the forensic and judicial markets. De Ridder will use this understanding to grow her activities in The Netherlands and internationally. ”

Hubert Verbeek managing partner of Holland Venture, comments: “With her large product range and the ability to translate customer wishes to new products, De Ridder has gained a very attractive position in the market. Together with the current management team, we see great opportunities to expand and further develop the company in existing markets as well as adjacent niches.”

20
jul
2012

Holland Venture sold its shares in software company BlueCielo

Holland Venture is pleased to announce that an agreement has been made to sell its shares in BlueCielo, as part of a management buyout, to Gilde Equity Management and the management of the company. During the participation of Holland Venture the company grew from a SME to a global professional software provider. We believe this management buy-out brings will create much added value for the next stage in the development of the company and wishes the new shareholders all the best with their new ambitions.

BlueCielo, founded in 1985, has over 300.000 users across more than 50 countries. BlueCielo ECM Solutions is a world leader in sophisticated software solutions in Asset Information Management and Engineering Content Management for owner/operators, and engineering document control for engineering, procurement and construction projects. BlueCielo focusses on capital-intensive process industries where technical documentation needs to be integrated in the customers’ management system. Through this software a better monitoring and management system can be realized, resulting in a more efficient resource allocation process, lower maintenance costs and a better risk-management implementation.

12
jul
2012

Holland Venture and healthcare insurer Menzis invest in innovative healthcare companies

Holland Venture launches in cooperation with healthcare insurer Menzis and various other investors a new 8 million euro venture capital fund, Holland Venture Health Innovation Fund. The fund targets to  invest in young, innovative, Dutch-based care companies with significant growth potential. Holland Venture Health Innovation Fund aims at establishing a portfolio of 10 innovative healthcare start-ups, provided with active support in their further development to maximize financial and healthcare return, making health care better and less expensive.

Holland Venture Health Innovation Fund  is a cooperation between Holland Venture, healthcare insurer Menzis and  several other investors. The Dutch government supports the fund with a seed capital regulation, an incentive arrangement  provided by the Ministry of Economic Affairs, Agriculture and Innovation (EAI).

According to Holland Venture, the health care industry remains interesting with its recent political en social developments. Demand for medical care has grown and resulted in a cost explosion in recent years.  If this development continues, healthcare becomes unaffordable on the short run, a undesirable situation in today’s civil society. Holland Venture Health Innovation Fund  supports entrepreneurs developing products and services improving the quality and value of healthcare and making it less expensive.

Innovative companies often lack the required  entrepreneurial experience and the necessary funding.  Holland Venture Health Innovation Fund intents to fulfill this role, by offering capital, sector-specific knowledge, experience and active involvement. Holland Venture’s team combines a relevant network, extensive private equity experience and a broad range of expertise and knowledge within the healthcare industry. The involvement of former cardiologist, healthcare director Jan Zijlstra and healthcare entrepreneur Jaap Maljers strengthens the care-related knowledge and its network within the healthcare industry. The combination of knowledge and experience is employed to actively support the portfolio companies in realizing their growth ambitions. Menzis shares its vision with Holland Venture and represents protecting  qualitative good healthcare and securing affordable healthcare in the future. With their involvement in the Holland Venture Care Innovation Fund Menzis invest in sustainable healthcare, accessible now and in the future. As sustainable health care insurer Menzis feels it her duty to stimulate innovations in healthcare.

22
may
2012

Holland Venture accelerates growth of learning and development institute Opdidakt

Holland Venture accelerates growth of learning and development institute Opdidakt
Private equity firm Holland Venture invests in children’s learning and development institute Opdidakt. The investment enables Opdidakt to realize its growth strategy and further professionalise its services.

Founded in 1998, Opdidakt focuses on children from 4 till 21 years old who have difficulties in their learning and development abilities/capabilities. As a fully certified institute it offers a wide range of services like dyslexia, remedial teaching, 1st and 2nd line psychology, socio-emotional support and homework supervision. In collaboration with schools and the children’s parents  Opdidakt helps children with their disabilities. Opdidakt has a strong reputation known for its skilled and dedicated staff providing high-quality care and support. Opdidakt has offices in Heesch, Gemert, Rosmalen, Etten-Leur, Boxmeer, Sevenum and Druten/Tiel that covers the geographical regions Noord-Brabant, Noord-Limburg and a part of Gelderland.

Henk van de Water, CEO and founder of Opdidakt: “There is an increasing need for qualitative education and support. However, the government is limiting their contribution in Dutch education due to required national savings. These developments create interesting business opportunities for private institutions, like Opdidakt. As an experienced growth investor, Holland Venture is a strong shareholder that will help us realize our growth ambitions and upgrade the quality and expertise of our services.”
Hubert Verbeek, managing partner Holland Venture, comments: “We are very excited about this investment. Opdidakt is situated in an interesting and dynamic market. Not only an increased attention and recognition for health and learning problems for children can be identified, but the demand for treatment grows as well. In the last ten years Opdidakt managed to develop itself as a leading player in its region. Nevertheless, both Holland Venture and Opdidakt see many growth opportunities in these and corresponding areas and are convinced these ambitions can be realized in close cooperation with Mr. van de Water.”

Holland Venture is an independent private equity firm located in Amsterdam. Founded in 1981, Holland Venture has successfully realized the growth potential of many of its investments. Throughout its 30 year existence, Holland Venture has proven to be a reliable and solid partner with a wide expertise in financing and strategic matters. Holland Venture is focusing on four themes; ageing, deregulation, sustainability and business succession. Its current fund focuses on growth, buy-out and buy-ins in the Benelux.

12
jan
2012

Stef Hinfelaar joined the HighCare Management Board

Stef Hinfelaar joined the HighCare Management Board, the leading provider of staffing solutions in critical functions in the healthcare sector.

As of January 1st, 2012 Hinfelaar is added as a member of the HighCare management board. As director and shareholder of Vitae, acquired in March 2008 by Manpower, Hinfelaar already experienced working in the flex- and staffing agency industry. After the acquisition Hinfelaar remained associated with Manpower as interim CFO in Germany, till the summer of 2010.

Hubert Verbeek, managing partner Holland Venture and Shareholder of HighCare is pleased with the reinforcement: “Stef Hinfelaar is a real gain for HighCare both in a personal and business perspective. With Stef a highly skilled and reliable manager reinforces the management board; we look forward to our future cooperation”.

Hans van Seters, CEO of HighCare adds: “I am pleased with the reinforcement. Stef Hinfelaar brings more then ten years of staffing solutions experience into the company”
Hinfelaar will focus on the strategy and organisation of HighCare in close cooperation with the current management. In addition he will concentrate on the further expansion of the organisation by organic growth or by add-on acquisitions in the healthcare sector.

HighCare is a leading supplier of staffing solutions for specialized clinical care for Dutch hospitals and other medical institutes since January 2000. The employees work in the (acute) ambulance service and/or in the (specialized) clinical care (including A-nurses, emergency room, ICU, CCU, OK, MC). Furthermore, HighCare has an Interim & Consultancy division that executes operational and strategic assignments for the healthcare sector.

23
dec
2011

Holland Venture invests in SEHV as HighCare add-on

Amsterdam, December 23 - Private equity firm Holland Ventures acquires SEHV as add-on for HighCare. Staffing agency SEHV will merge with subsidiary AmbuCare. The SEHV acquisition offers HighCare the opportunity to position itself further as a leading provider of professional health care services, offering continuity in staffing solutions within the Dutch healthcare sector.

As a staffing agency, SEHV provides both nurses and doctors for the emergency departments of hospitals. Both SEH-nurses and SEH-doctors are employed. SEHV’s operations are mainly focused in the south of the Netherlands and Amsterdam, however, its customer base consists of nearly all hospitals with an emergency department. The acquisition of SEHV is a beneficial addition to AmbuCare services. By acquiring SEHV it becomes possible to further intensify our healthcare partnerships with hospitals and to offer both clients and professionals more continuity. SEHV will be integrated into AmbuCare’s operations.

Harrie van Hellemond, director of SEHV, is pleased by the HighCare takeover: “When I decided to sell the company I found it important that the decision had no impact on either the professionals or the clients. The acquisition by HighCare will tender great advantages for SEHV’s professionals and clients. HighCare will integrate SEHV into AmbuCare operations. HighCare offers their professionals more continuity in their assignments and provides the opportunity to develop themselves at the Care Academy of HighCare. Clients also benefit from this acquisition, as Highcare can supply more continuity in providing temporarily medical staff.

Hubert Verbeek, managing partner Holland Venture, comments:”Early 2010 Holland Venture invested in HighCare, aiming to build a leading staffing specialist in the healthcare sector. In May of this year the merger with AmbuCare was realized. Together they act as a stronger and more reliable partner in the health care sector. The acquisition of SEHV, integrated as a subsidiary of AmbuCare, enables HighCare to offer more continuity to her clients. She offers a wide range of IC-nurses, anesthesia staff, ambulance staff and control room dispatchers.   

HighCare is a leading supplier of staffing solutions for specialized clinical care for Dutch hospitals and other medical institutes since January 2000. Furthermore, HighCare has an Interim & Consultancy division that executes operational and strategic assignments for the healthcare sector.

AmbuCare (founded in 2001) is a medium-sized staffing organization in the healthcare sector. The employees work in the (acute) ambulance service and/or in the (specialized) clinical care (including A-nurses, emergency room, ICU, CCU, OK, MC). AmbuCare also offers physicians for staffing solutions. In May 2011 AmbuCare merged with HighCare.

Holland Venture is an independent private equity firm located in Amsterdam. Founded in 1981, Holland Venture has successfully realized the growth potential of many of its investments. Throughout its 30 year existence, Holland Venture has proven to be a reliable and solid partner with a wide expertise in financing and strategic matters. Holland Venture is focusing on four themes; ageing, deregulation, sustainability and business succession. Its current fund focuses on growth, buy-out and buy-ins in the Benelux.

31
oct
2011

Holland Venture invests in the niche travel company Institute of Travel

Private equity firm Holland Venture invests in the travel company Institute of Travel (IOT). IOT is an organization that offers distinctive travel products in attractive niche markets. As IOT primarily targets the senior segment of the population, this transaction fits perfectly with the investment strategy of Holland Venture. The investment enables IOT to realize  its growth strategy.

Established in 1988, IOT is an independent travel organization which offers both individual and group travel packages with destinations all over the world. IOT’s product range consists of unique tours with a distinctive cultural component and high quality guidance. IOT addresses the needs of different target groups through ten labels. 

Otto-Mark Schaap and Paul Vigeveno will continue to manage IOT from the Prinsengracht location in Amsterdam. Paul Vigeveno: “Our target group is growing, travels frequently and is willing to pay for these unique cultural tours. We have a good understanding of the needs of our customers and are able to fulfill these needs in a distinctive manner.” Otto-Mark Schaap continues: “We see interesting opportunities for expansion of our activities. As an experienced growth investor, Holland Venture is the right partner to help us realize our ambitions and expand our product offering in a professional way.”

Ewout Prins, managing partner Holland Venture, comments: “We are very excited about this investment as it fits well with the ageing theme of our investment focus. IOT has an extensive cultural network, a strong reputation and over 20 years of experience in the travel industry.  Moreover, we see many autonomous growth opportunities in this specific market segment. In addition, new target groups could be approached by new channels and further product development is achievable. Furthermore we believe there are interesting buy-and-build opportunities in this fragmented market.”

Holland Venture is an independent private equity firm located in Amsterdam. Founded in 1981, Holland Venture has successfully realized the growth potential of many of its investments. Throughout its 30 year existence, Holland Venture has proven to be a reliable and solid partner with a wide expertise in financing and strategic matters. Holland Venture is focusing on four themes; ageing, deregulation, sustainability and business succession. Its current fund focuses on growth, buy-out and buy-ins in the Benelux.

01
dec
2011

Holland Venture facilitates merger HighCare and AmbuCare with growth capital

Private equity firm Holland Venture invests in AmbuCare, a staffing agency in ambulance care, to initiate a merger with its portfolio company HighCare. The investment enables HighCare and AmbuCare to act as a stronger and more reliable partner in staffing solutions for hospitals and regional ambulance services. Furthermore, both companies’ education institutes are now able to offer a broader range of training possibilities. The combined organization employs over 300 professionals and has a pool of 1.000 temporary workers.

Both HighCare and AmbuCare are established providers of staffing solutions in the healthcare sector. They have similar strategies regarding quality, partnership and innovation and put emphasis on good employment practices . This collaboration was fueled by the rapid developments in the healthcare sector, particularly the increasing shortage of employees, the aging population and the increasing demand from hospitals and regional ambulance services for a reliable partner that can guaranty quality. With this merger a solid partner has emerged that can guarantee this quality over a wide range of professional disciplines, such as: surgical assistants, emergency and intensive care nurses, anesthesia personnel, ambulance personnel and emergency room specialists.
Hans van Seters, CEO HighCare, sees substantial benefits for its clients and employees: “AmbuCare is a company where quality, reliability and good employment is the center of the strategy, just like HighCare. The merger with AmbuCare enables us to improve the partnership with our customers; together we can offer a wider range of professional disciplines and strengthen our geographical coverage. For our employees this collaboration brings advantages in terms of improved training and personal development possibilities.”

Jan Swagemakers, CEO AmbuCare, elaborates on that: “I am very satisfied with the cooperation between HighCare and AmbuCare. In the ever-changing healthcare sector, hospitals and regional ambulance services have an increasing need for a solid partnership with a strong focus on quality, reliability and continuity. By joining forces, we can respond to this demand better and reinforce our position in the market.”

Hubert Verbeek, managing partner Holland Venture: “Early 2010 Holland Venture invested in HighCare with the aim to make the company the leading player in staffing solutions for the healthcare sector. The collaboration with AmbuCare contributes significantly to this aim since the company can expand its services with a number of interesting disciplines. The merger of HighCare and AmbuCare provides a solid basis for future growth.”

AmbuCare (founded in 2003) is a medium-sized staffing organization in the healthcare sector. The employees work in the (acute) ambulance service and/or in the (specialized) clinical care (including A-nurses, emergency room, ICU, CCU, OK, MC). AmbuCare also offers physicians for staffing solutions.

HighCare is a leading supplier of staffing solutions for specialized clinical care for Dutch hospitals and other medical institutes since January 2000. Furthermore, HighCare has an Interim & Consultancy division that executes operational and strategic assignments for the healthcare sector.

Holland Venture, founded in 1981, is a private equity firm from Amsterdam. In their 29 years of existence, Holland Venture has proven to be a reliable and solid partner with extensive knowledge of financing and strategic development. The healthcare sector is playing an increasingly important role in the investment strategy of Holland Venture. The present fund aims at growth financing, management buy-out and management buy-ins in the Benelux area.

01
aug
2010

Investment Holland Venture seeks to accelerate growth of Interhealth

Private Equity firm Holland Venture invests in the innovative healthcare company Interhealth. This investment will enable Interhealth to accelerate its growth and moreover will contribute to the further increase of efficiency and affordability of the Dutch mental health care market. With this investment Holland Venture further establishes its position as a leading investor in the healthcare market.

Interhealth is an innovative healthcare company comprising of subsidiary organizations Mentaal Beter and Innohealth. Mentaal Beter is a patient-oriented provider of mental health care (GGZ). With more than 400 psychologists, psychiatrists and psychotherapists, the company offers high quality mental healthcare treatments through more than 100 practices  across the Netherlands. Using e-health programs and measurement systems developed by Interhealth and subsidiary Innohealth, Mentaal Beter is optimally positioned to offer treatment that are often more effective than traditional healthcare suppliers. As a result, Mentaal Beter was able to grow in six years to a company with a EUR 25 mio turnover.

Martin de Heer, chairman of the board Interhealth: “Through the increased need for mental care in society the mental healthcare sector is growing steadily the past years. The sector faces the challenge to reduce costs of healthcare while maintaining high quality standards. Interhealth combines personalized treatments in small-scale settings, with innovative e-health programs and outcome measurement of Innohealth. We see great potential in this combination and have great ambitions to further improve the Dutch healthcare. Personal attention, quality, efficiency, effectiveness and innovation are our focus areas. In Holland Venture we have found a partner who supports us in achieving our objectives. Through their investment, their valuable network in the health care sector and their knowledge and experience with growing businesses in evolving markets, Holland Venture is optimally suited to assist us in realizing our ambition.

Ewout Prins, Managing Partner of Holland Venture clarifies: “We are very excited with this investment as it fits well with the ageing issues and deregulation of our investment focus. The health care sector is an industry in motion. Innovative businesses should help the industry to become more professional. An efficient design of processes with greater emphasis on transparency and quality of care outcomes will lead to more affordable high quality health care. In the mental health care industry we see Interhealth as an organization who is leading in this area, an organization where others can take an example of.”

Holland Venture is an independent private equity firm located in Amsterdam. Founded in 1981, Holland Venture has successfully realized the growth potential of many of its investments. Throughout its 29 year existence, Holland Venture has proven to be a reliable and solid partner with a wide expertise in financing and strategic matters. Holland Venture is focusing on four themes, of which the healthcare sector is a important example of. Established in 2009 its current fund, with a size of 70 million euro, focuses on growth, buy-out and buy-in investments in the Benelux.

Holland Venture previously invested in various other health care related companies such as High Care, a human capital partner for hospitals and AOV, a supplier of high quality nutritional supplements. Holland Venture will do more investments in this sector in the near future.


01
jul
2010

HighCare is expanding its services with High Care Flex

From July 1, 2010 HighCare, the Human Capital partner for the medical- and healthcare sector, is expanding its services by introducing the ‘High Care Flex’. Through this Flexbureau, HighCare is now also able to provide healthcare professionals for a period of 1 day to 1 month (in addition to its secondment service of providing professionals from  1 month to 1 year). This initiative is HighCare’s response to the increasing demand for flexible healthcare staff. 

Since January 2000, HighCare is one of the most prominent Human Capital partners for Dutch hospitals and medical organizations. HighCare is known for providing high quality medical professionals, including highly educated specialized nurses, surgery assistants, interim-managers, project managers and organizational advisers in the health sector. The company, founded by Jaap Kooimans and Hans van Seters, is located in Rotterdam and Amsterdam and currently employs 150 professionals.

Hospitals consider HighCare as a valuable partner to deal with the increasing shortage of qualified employees, for both long and short term. HighCare gained prominence through its innovative initiative of ‘mobile surgery teams’. By involving such flexible teams, hospitals can realize substantial productivity improvements and effectively address both the issues of waiting lists as well as the fulfillment of additional production capacity.

Since January 2010 Holland Venture is involved as an active shareholder of HighCare. The goal of this collaboration is  to become the HR partner for organizations in the healthcare and medical sector. The first expansion of High Care’s services is presented in the ‘HighCare Employment Agency’. Previous years HighCare was focussed on the offering of healthcare professionals for a period of 1 month to 1 year. Since July the first, High Care is also providing professionals for 1 day to 1 month. The agency focuses on completing its (very) short-term assignments. Het onderlijnde stuk staat ook al in de eerste paragraaf van dit nieuwsbericht. Initially the agency will focus on specialized care, OK, recovery, ICU, emergency department and dialysis. Especially for this expansion two new recruiters are hired; Vera Brugging and Annemarie van Asselt. Both have a lot of employment agency experience.

Hans van Seters, CEO HighCare: "At the request of our clients, we have expanded our services. With the creation of HighCare Flex we try to respond to the increasing demand for flexible healthcare staff in the short term. Through this initiative HighCare is able to provide short-term supply of HighCare employees on short notice. HighCare Flex is a new activity which allows us to further meet the demands of our clients”.

 Vera Brugging: "HighCare Flex focuses on the short-term placement of specialized nurses and paramedics. We are the solution for flexible care professionals who seek to work in several hospitals and be the boss of their  own agenda".

Annemarie van Asselt adds: "Clients may submit an application to us and care professionals can indicate their availability to us. We make sure that supply and demand will meet each other and we ensure to place the right person at the right place".

Later this year, HighCare is planning to introduce more services, including the development and implementation of the HighCare Academy.

12
jan
2010

Holland Venture invests in growth of medical staffing company High Care

As of the 12th of January 2010 private equity firm Holland Venture has invested a significant amount in medical staffing specialist High Care, which firm is active in the medical industry. With this investment, High Care will accelerate its growth and obtain an acquisition fund of 5 million euros to expand in this attractive market. Holland Venture expects to be actively involved with the company for a period of 5 to 7 years.

Since January 2000, High Care is one of the most prominent medical staffing specialists for the Dutch hospitals and medical industries. The company, founded by Jaap Kooimans and Hans van Seters, is located in Rotterdam and employs 150 professionals. High Care provides highly educated specialized nurses, surgery assistants, interim-managers, project managers and organizational advisers in the health sector. High Care is known for its solid and high-quality reputation. The company has grown rapidly and will continue to expand its activities .

Hospitals consider High Care as a valuable partner to deal with the increasing shortage of qualified employees, for both long and short term. High Care gained prominence through its innovative initiative of ‘mobile surgery teams’. By involving such flexible teams, hospitals can realize substantial productivity improvements and effectively address the issues of waiting lists and fulfillment of additional production capacity.

Hans van Seters, managing director of High Care; “There are numerous opportunities in the medical and health market where a human capital partner can provide excellent added value. High Care has high ambitions which can be realized and expanded through this investment”. Jaap Kooimans, managing director of High Care clarifies: “Holland Venture is a valuable shareholder with significant expertise in the healthcare sector and medical staffing market. Within the healthcare sector they will offer us professional expertise to operate in a stronger and more efficient manner”.

Hubert Verbeek, managing partner of Holland Venture clarifies: ‘We are very excited about this investment in High Care; the transaction optimally fits in our investment focus. High Care has a strong reputation and has obtained an unique position in the Dutch healthcare market. Central to this position are the high quality services that High Care provides.  We see many growth opportunities for this human capital provider in the healthcare sector and we are convinced that the management of High Care possesses the right capabilities and ambitions to realize these opportunities”.

01
oct
2009

Joep de Groot joined the Holland Venture Advisory Board

In October 2009 Joep de Groot joined the Holland Venture Advisory Board. We consider his expertise on the Dutch Healthcare of great value to our activities and hence we are very pleased to have Joep de Groot on our team.

Joep de Groot is an experienced strategy consultant. He has advised both start-up companies as well as reputable, established ones, on competitive strategy, mergers and acquisitions and their pursuit of innovation. Moreover, in the capacity as its CEO, he has built multiple organizations from scratch. As a result of these activities, his experience and expertise span various branches, but is most strongly expressed in the insurance, healthcare and ICT sectors. Within the healthcare sector Joep has executed several projects for general practitioners, hospitals, home care, nursing homes, welfare institutions and organizations for the disabled. Recently he worked as an Interim Director Marketing at the health insurance company CZ. Moreover, he initiated several innovative programs within the Dutch healthcare market, such as Medicinfo, Medic Support Team, Triage Software (Plain) and chain care (Dotmed). Due to his extensive work experience as well as his innovative approach, he is able to transform ideas into real developments that have a strong impact on the Dutch healthcare system.

01
jul
2009

Holland Venture establishes new private equity fund

Holland Venture has established a new 70 million euro private equity fund aimed at expansion and buy-out investments in the Benelux. The fund targets existing companies with an enterprise value between 5 and 50 million euro, that can benefit from the following long term trends:
  • Effects of deregulation
  • Demographic developments
  • Sustainability
  • Ownership transmission
The fund will acquire majority stakes or minority stakes with control rights and invests equity amounts of 3 to 13 million euro.

This new fund is the fifth fund managed by the Holland Venture organisation. The fund is headed by managing partners Hubert Verbeek and Ewout Prins, who have an extensive experience in the Dutch private equity market. They both worked as investment managers for the previous Holland Venture fund and Verbeek also worked as director for Rabo Private Equity. They took over the helm from Holland Venture’s founder Rolf Deves, who is managing partner of the four previous Holland Venture funds. Deves has a vast experience with all aspects of company development and private equity transactions and shall be associated with the new fund through his role in the Advisory Board. Jos Houben is the third partner of the team. Houben is an experienced entrepreneur and investor with an broad track record, amongst others in deregulation projects.

Furthermore, the team consists of two experienced analysts, a legal expert and a financial specialist.

The new Holland Venture fund is sponsored by Natixis Private Equity (NPE), the private equity branch of the French investment bank Natixis. Leader in France in private equity devoted to SMEs, NPE is also a leading player in Europe with a rising profile in the high potential markets of Asia, South America and India. NPE is active in all areas of Private Equity – Venture, Expansion, Transmission and Funds of funds – with 18 teams, 194 professionals, 695 equity investments and more than 4 billion dedicated to the growth of SMEs.

22
sep
2008

Holland Venture sold its shares in Orthos Europe to Atrium Innovations

Holland Venture has sold its shares in Orthos Europe B.V.. Orthos Europe BV maintains 100% of the shares of AOV Orthomoleculaire Voedingssupplementen BV (Orthomolecular Food supplements), a company which develops and distributes highly dosed food supplements. The purchaser is Atrium Innovations, a Canadian stock market listed company and a global player in the field of high quality  food supplements. With this acquisition Holland Venture realized an excellent return on the equity they acquired in 2005.

Investment Manager Ewout Prins of Holland Venture clarifies: “The high quality of their products and leading expertise  is distinctive for AOV. AOV developed itself successfully since the management buy-out in 2005. They have strengthened their market position, the organization further professionalized and they expanded their service and education offerings to customers and physicians. Through the connection with Atrium Innovations  AOV is gaining access to valuable technology, innovation and scientific research with which they can intensify their Dutch and European position.

We have experienced a positive cooperation with the management of AOV and we wish them a successful future as a part of Atrium Innovations.

09
jun
2008

Holland Venture sold its shares in Sunday`s International to management.

Holland Venture has sold its shares in Sunday’s International to the management of the company, which is lead by CEO Rob Bontje. Holland Venture realized an excellent return on the equity which they acquired in 2005.

Investment Manager Ewout Prins of Holland Venture clarifies: “Sunday’s has realized an remarkable growth and development since 2005. Sunday’s is a professional organization remains the unchallenged market leader in the field of solariums in The Netherlands. We have experienced a pleasant and constructive cooperation with the management of Sunday’s and we wish them all the best with the further expansion of their company”.

12
sep
2007

Holland Venture to sell its shares in INS Group S.A



Holland Venture is pleased to announce that it agreed to sell its shares in INS Group, a Belgium-based network and systems integrator, to BT who agreed to acquire 100% of the shares of INS Group.



BT is one of the world’s leading providers of communications solutions and services.



Holland Venture has been an investor in the company since 2001 and was the largest shareholder of INS Group.

Contact
Holland Venture Management B.V.
Franz Zieglerstraat 24
1087 HN Amsterdam
The Netherlands

T. +31 (0) 20 3119411
info@hollandventure.com
Social



Language